Allogene Therapeutics, Inc. (ALLO) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Oil gains over 3% as US-Iran peace talks in stalemate
- Stock action shows confidence in central banks: BofA’s Hartnett
- Trump says men arrested at UK air base used by US were looking to do 'big damage'
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- Oppenheimer sees AI software winners as focus shifts to ROI
- Dollar near two-month high as US-Iran stalemate bolsters oil, Fed rate hike bets
- BofA Securities Starts IonQ, Inc. (IONQ) at Buy
Truist Securities Reiterates Buy Rating on Allogene (ALLO)
May 14, 2024 8:03 AM EDTTruist Securities analyst Asthika Goonewardene reiterated a Buy rating and $17.00 price target on Allogene (NASDAQ: ALLO)
The analyst comments "Two key positives from 1Q24 should make the stock more attractive, in our view: (1) Gaining EU/UK rights to lead asset... More
